Silence Therapeutics (SLN) Total Liabilities (2018 - 2026)

Silence Therapeutics has reported Total Liabilities for 3 years, with the latest figure at $65.7 million in Q1 2026.

• Quarterly Total Liabilities fell 9.42% year-over-year to $65.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.7 million (down 9.42% YoY) and the FY2025 annual result came in at $69.1 million, up 0.77% from the prior year.
• Total Liabilities declined to $65.7 million in Q1 2026 per SLN's latest filing, from $69.1 million in the prior quarter.
• Over five years, Total Liabilities peaked at $72.7 million in Q3 2025 and troughed at $65.7 million in Q1 2026.
• A 3-year average of $70.0 million and a median of $70.1 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities advanced 0.77% in 2025, then dropped 9.42% in 2026.
• Over 3 years, Total Liabilities stood at $68.6 million in 2024, then increased by 0.77% to $69.1 million in 2025, then dropped by 4.94% to $65.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $65.7 million, $69.1 million, and $72.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.